Drugs / EBV gp350-Ferritin vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06908096 | May 2025 → Oct 2027 expected | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT04645147 | Mar 2022 → Jul 2025 overdue | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV gp350-ferritin vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06908096 ↗ |
| Modality | Vaccine | “3-dose vaccination regimen of an adjuvanted EBV gp350-Ferritin nanoparticle vaccine” NCT04645147 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT04645147 ↗ |